论文部分内容阅读
作者对２３例无法切除的晚期原发性肝癌采用经皮下埋藏式灌注装置行肝动脉和门静脉双介入治疗。其中１６例应用超液态碘油加化疗药物行肝动脉化疗栓塞加门静脉灌注化疗；７例单纯灌注化疗。在栓塞组有症状的１３例中，１２例获得缓解；在ＡＦＰ＞４００μｇ／Ｌ的１３例中，７例下降。平均生存期为８．４月，半年生存率为的４４％。化疗组有症状的６例中，３例部份缓解；ＡＦＰ＞４００μｇ／Ｌ的４例中１例下降。平均生存期为５．８６月，半年生存率为１４．３％。栓塞组的治疗效果比单纯化疗组为佳。
Twenty-three patients with unresectable advanced primary liver cancer underwent dual interventional treatment with hepatic artery and portal vein via subcutaneously implanted perfusion device. Among them, 16 cases were treated with hepatic arterial chemoembolization and portal vein infusion chemotherapy with hyper-liquid lipiodol plus chemotherapeutic agents; 7 cases were treated with chemotherapy alone. Of the 13 patients who had symptoms in the embolization group, 12 patients had remission; in 13 patients who had an AFP of >400 μg/L, 7 patients had decreased. The average survival period is 8.4 months and the half-year survival rate is 44%. Of the 6 patients who had symptoms in the chemotherapy group, 3 had partial remission; 1 of 4 patients with AFP> 400 μg/L had a decrease. The average survival period was 5.86 months, and the half-year survival rate was 14.3%. The embolization group was better than the chemotherapy alone group.